X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4922) 4922
Publication (547) 547
Book Review (113) 113
Book Chapter (35) 35
Dissertation (10) 10
Conference Proceeding (9) 9
Government Document (6) 6
Book / eBook (4) 4
Magazine Article (3) 3
Data Set (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3530) 3530
female (3325) 3325
index medicus (2542) 2542
breast cancer (2309) 2309
aromatase inhibitors (2187) 2187
breast neoplasms - drug therapy (2181) 2181
oncology (2083) 2083
postmenopausal women (1869) 1869
tamoxifen (1608) 1608
letrozole (1571) 1571
aromatase inhibitors - therapeutic use (1354) 1354
middle aged (1096) 1096
estrogen (1086) 1086
aromatase inhibitor (1013) 1013
cancer (983) 983
anastrozole (974) 974
aged (911) 911
aromatase (868) 868
antineoplastic agents, hormonal - therapeutic use (836) 836
breast neoplasms - pathology (826) 826
endocrine therapy (809) 809
triazoles - therapeutic use (802) 802
nitriles - therapeutic use (800) 800
randomized-trial (788) 788
care and treatment (768) 768
adult (751) 751
postmenopause (743) 743
animals (735) 735
tamoxifen - therapeutic use (679) 679
women (644) 644
obstetrics & gynecology (638) 638
treatment outcome (635) 635
endocrinology & metabolism (621) 621
medicine & public health (621) 621
aromatase inhibitors - adverse effects (600) 600
chemotherapy, adjuvant (548) 548
aromatase inhibitors - pharmacology (546) 546
breast neoplasms - metabolism (525) 525
health aspects (505) 505
analysis (501) 501
therapy (485) 485
exemestane (484) 484
research (477) 477
male (475) 475
triazoles - pharmacology (441) 441
antineoplastic agents - therapeutic use (431) 431
nitriles - pharmacology (427) 427
aromatase inhibitors - administration & dosage (426) 426
chemotherapy (416) 416
triazoles - administration & dosage (408) 408
nitriles - administration & dosage (407) 407
drug therapy (401) 401
aromatase - metabolism (397) 397
pharmacology & pharmacy (380) 380
aged, 80 and over (369) 369
double-blind (363) 363
receptors, estrogen - metabolism (360) 360
adjuvant treatment (351) 351
biochemistry & molecular biology (350) 350
estradiol (348) 348
article (341) 341
expression (336) 336
breast-cancer (324) 324
first-line therapy (302) 302
tamoxifen therapy (299) 299
clinical trials as topic (293) 293
reproductive biology (293) 293
hematology, oncology and palliative medicine (290) 290
risk factors (290) 290
disease-free survival (284) 284
megestrol-acetate (279) 279
nitriles - adverse effects (278) 278
triazoles - adverse effects (278) 278
neoplasms, hormone-dependent - drug therapy (275) 275
clinical trials (274) 274
pregnancy (274) 274
trial (272) 272
antineoplastic agents, hormonal - adverse effects (268) 268
breast neoplasms - genetics (262) 262
metastasis (262) 262
randomized controlled trials as topic (258) 258
menopause (256) 256
androstadienes - therapeutic use (254) 254
internal medicine (254) 254
antineoplastic combined chemotherapy protocols - therapeutic use (249) 249
phase-iii (247) 247
obstetrics and gynecology (246) 246
testosterone (239) 239
breast neoplasms - mortality (235) 235
prevention (235) 235
enzyme inhibitors - therapeutic use (232) 232
estrogen-receptor (229) 229
neoplasm staging (226) 226
estradiol - blood (223) 223
osteoporosis (222) 222
hormones (218) 218
tamoxifen - administration & dosage (215) 215
estrogens (214) 214
mice (213) 213
aromatase - genetics (208) 208
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4843) 4843
French (41) 41
German (38) 38
Japanese (9) 9
Chinese (8) 8
Russian (7) 7
Spanish (6) 6
Korean (4) 4
Italian (3) 3
Polish (3) 3
Czech (2) 2
Dutch (2) 2
Hungarian (2) 2
Portuguese (2) 2
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine... 
ACTIVATION | NVP-BYL719 | PIK3CA MUTATIONS | PI3K | ONCOLOGY | PHOSPHATIDYLINOSITOL 3-KINASE | GROWTH | ESTROGEN DEPRIVATION | RESISTANCE | ALPHA | TUMORS | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Safety engineering | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Breast | Antitumor activity | Tumors | DNA sequencing | Cancer
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 11/2014, Volume 351, Issue 2, pp. 270 - 277
Journal Article
European Journal of Obstetrics & Gynecology and Reproductive Biology, ISSN 0301-2115, 2013, Volume 171, Issue 2, pp. 329 - 332
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 02/2017, Volume 17, Issue 2, pp. 191 - 197
Background: Studies have demonstrated that cysteine-rich 61 (CYR61) may be involved in tumor proliferation and invasion. However, the role of CYR61 plays in... 
CYR61/CNN1 | Estrogen receptor | Sensitivity | Breast cancer | Aromatase inhibitor | ANGIOGENIC FACTOR | estrogen receptor | CCN FAMILY | breast cancer | ENDOCRINE THERAPY | TISSUE GROWTH-FACTOR | ONCOLOGY | ESTROGEN | RESISTANCE | sensitivity | CANCER PROGRESSION | EXPRESSION
Journal Article
Journal Article
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 05/2014, Volume 141, pp. 37 - 43
Journal Article
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2010, Volume 93, Issue 1, pp. 192 - 198
Journal Article
Journal of Hazardous Materials, ISSN 0304-3894, 07/2014, Volume 277, pp. 141 - 149
Letrozole (LET) is a triazole-containing drug that can inhibit the activity of cytochrome P450 aromatase. It is an environmentally emerging pollutant because... 
Aromatase inhibitor | Cytochrome P450 (CYP)